These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 19197732)

  • 1. Impairment of peripheral blood stem-cell mobilisation in patients with mantle-cell lymphoma following primary treatment with fludarabine and cyclophosphamide +/- rituximab.
    Eve HE; Seymour JF; Rule SA
    Leuk Lymphoma; 2009 Mar; 50(3):463-5. PubMed ID: 19197732
    [No Abstract]   [Full Text] [Related]  

  • 2. The Simplified Mantle-Cell Lymphoma International Prognostic Index predicts overall survival but not progression-free survival in patients with mantle-cell lymphoma treated with fludarabine and cyclophosphamide +/- rituximab: results of a randomized phase II trial.
    Eve HE; Gambell J; Smith P; Qian W; Rule SA
    Leuk Lymphoma; 2009 Oct; 50(10):1709-11. PubMed ID: 19757310
    [No Abstract]   [Full Text] [Related]  

  • 3. Superior quality and duration of responses among patients with mantle-cell lymphoma treated with fludarabine and cyclophosphamide with or without rituximab compared with prior responses to CHOP.
    Thomas DW; Owen RG; Johnson SA; Hillmen P; Seymour JF; Wolf MM; Rule SA
    Leuk Lymphoma; 2005 Apr; 46(4):549-52. PubMed ID: 16019483
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Mantle cell lymphoma].
    Ogura M
    Rinsho Ketsueki; 2001 Apr; 42(4):281-7. PubMed ID: 11400298
    [No Abstract]   [Full Text] [Related]  

  • 5. A model of in vivo purging with Rituximab and high-dose AraC in follicular and mantle cell lymphoma.
    Arcaini L; Orlandi E; Alessandrino EP; Iacona I; Brusamolino E; Bonfichi M; Bernasconi P; Calatroni S; Tenore A; Montanari F; Troletti D; Pascutto C; Regazzi M; Lazzarino M
    Bone Marrow Transplant; 2004 Jul; 34(2):175-9. PubMed ID: 15170171
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Successful in vivo purging of CD34-containing peripheral blood harvests in mantle cell and indolent lymphoma: evidence for a role of both chemotherapy and rituximab infusion.
    Magni M; Di Nicola M; Devizzi L; Matteucci P; Lombardi F; Gandola L; Ravagnani F; Giardini R; Dastoli G; Tarella C; Pileri A; Bonadonna G; Gianni AM
    Blood; 2000 Aug; 96(3):864-9. PubMed ID: 10910898
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Toxicity of fludarabine and cyclophosphamide with or without rituximab as initial therapy for patients with previously untreated mantle cell lymphoma: results of a randomised phase II study.
    Eve HE; Linch D; Qian W; Ross M; Seymour JF; Smith P; Stevens L; Rule SA
    Leuk Lymphoma; 2009 Feb; 50(2):211-5. PubMed ID: 19197729
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotherapy with rituximab following high-dose therapy and autologous stem-cell transplantation for mantle cell lymphoma.
    Mangel J; Buckstein R; Imrie K; Spaner D; Crump M; Tompkins K; Reis M; Perez-Ordonez B; Deodhare S; Romans R; Pennell N; Robinson JB; Hewitt K; Richardson P; Lima A; Pavlin P; Berinstein NL
    Semin Oncol; 2002 Feb; 29(1 Suppl 2):56-69. PubMed ID: 11842390
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rituximab plus chemotherapy in follicular and mantle cell lymphomas.
    Hiddemann W; Dreyling M; Unterhalt M
    Semin Oncol; 2003 Feb; 30(1 Suppl 2):16-20. PubMed ID: 12652460
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of older patients with mantle-cell lymphoma.
    Kluin-Nelemans HC; Hoster E; Hermine O; Walewski J; Trneny M; Geisler CH; Stilgenbauer S; Thieblemont C; Vehling-Kaiser U; Doorduijn JK; Coiffier B; Forstpointner R; Tilly H; Kanz L; Feugier P; Szymczyk M; Hallek M; Kremers S; Lepeu G; Sanhes L; Zijlstra JM; Bouabdallah R; Lugtenburg PJ; Macro M; Pfreundschuh M; Procházka V; Di Raimondo F; Ribrag V; Uppenkamp M; André M; Klapper W; Hiddemann W; Unterhalt M; Dreyling MH
    N Engl J Med; 2012 Aug; 367(6):520-31. PubMed ID: 22873532
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prolonged immunochemotherapy with rituximab, cytarabine and fludarabine added to cyclophosphamide, doxorubicin, vincristine and prednisolone and followed by rituximab maintenance in untreated elderly patients with mantle cell lymphoma: a prospective study by the Finnish Lymphoma Group.
    Räty R; Honkanen T; Jantunen E; Jyrkkiö S; Karjalainen-Lindsberg ML; Kuittinen O; Lehto M; Mikkola M; Poikonen E; Rauhala A; Rimpiläinen J; Räsänen A; Siitonen S; Suominen M; Vapaatalo M; Elonen E
    Leuk Lymphoma; 2012 Oct; 53(10):1920-8. PubMed ID: 22397313
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment with hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone combined with cytarabine and methotrexate results in poor mobilization of peripheral blood stem cells in patients with mantle cell lymphoma.
    Hill BT; Rybicki L; Smith S; Dean R; Kalaycio M; Pohlman B; Sweetenham J; Tench S; Sobecks R; Andresen S; Copelan E; Bolwell BJ
    Leuk Lymphoma; 2011 Jun; 52(6):986-93. PubMed ID: 21314484
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fludarabine, cyclophosphamide, and rituximab chemotherapy followed by rituximab maintenance in follicular lymphoma: high efficacy may come at a cost?
    Tam CS; Seymour JF
    Leuk Lymphoma; 2011 May; 52(5):729-31. PubMed ID: 21504295
    [No Abstract]   [Full Text] [Related]  

  • 14. [Treatment of chronic lymphocytic leukemia with regimen of fludarabine, cyclophosphamide and rituximab].
    Gu WJ; Xu W; Qian SX; Wu YJ; Hong M; Chen LJ; Wu HX; Lu H; Qiu HX; Li JY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Aug; 16(4):938-42. PubMed ID: 18718095
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fludarabine, cyclophosphamide, and rituximab for the treatment of patients with chronic lymphocytic leukemia or indolent non-Hodgkin lymphoma.
    Tam CS; Wolf M; Prince HM; Januszewicz EH; Westerman D; Lin KI; Carney D; Seymour JF
    Cancer; 2006 Jun; 106(11):2412-20. PubMed ID: 16649223
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rituximab plus fludarabine and cyclophosphamide or other agents in chronic lymphocytic leukemia.
    Robak T; Lech-Maranda E; Robak P
    Expert Rev Anticancer Ther; 2010 Oct; 10(10):1529-43. PubMed ID: 20942624
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rituximab therapy of severe aplastic anemia induced by fludarabine and cyclophosphamide in a patient affected by B-cell chronic lymphocytic leukemia.
    Castiglioni MG; Scatena P; Pandolfo C; Mechelli S; Bianchi M
    Leuk Lymphoma; 2006 Sep; 47(9):1985-6. PubMed ID: 17065021
    [No Abstract]   [Full Text] [Related]  

  • 18. Rituximab-induced life-threatening coagulopathy occurring in a patient with Waldenström macroglobulinemia treated with fludarabine, cyclophosphamide, and rituximab combination.
    Pilorge S; Park S; Dreyfus F; Bouscary D; Tamburini J
    Leuk Lymphoma; 2010 Dec; 51(12):2288-90. PubMed ID: 20929331
    [No Abstract]   [Full Text] [Related]  

  • 19. Fludarabine, Bortezomib, Myocet and rituximab chemotherapy in relapsed and refractory mantle cell lymphoma.
    Orciuolo E; Buda G; Pelosini M; Petrini M
    Br J Haematol; 2010 Mar; 148(5):810-2. PubMed ID: 19919649
    [No Abstract]   [Full Text] [Related]  

  • 20. Treatment-related acute myeloid leukemia with 11q23 translocation following treatment with fludarabine, cyclophosphamide and rituximab.
    Martin-Salces M; Canales MA; de Paz R; Hernandez-Navarro F
    Leuk Res; 2008 Jan; 32(1):199-200. PubMed ID: 17870157
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.